NR3C1 and neurodegenerative disease: This finding shows, at least in animals, that deactivation of the GR and/or recovery of the MR:GR balance may be a neuropharmaceutical treatment strategy for attenuating the damaging impact of hypercortisolemia in neurodegenerative diseases.